The Reference Guide to Integrate Smart Insulin Pens Into Data-Driven Diabetes Care and Education Services

Abstract

Purpose

More than 7 million Americans who have diabetes use insulin therapy. The majority continue to use syringes and vials or traditional insulin pens to deliver their insulin doses. Using these tools to deliver insulin presents numerous challenges for both the person with diabetes and their clinicians. This article provides an in-depth introduction to a new category of insulin delivery devices and integrated management systems, referred to as smart insulin pens. The article includes information about how these integrated insulin delivery systems can reduce many of the challenges of rapid-acting insulin dosing via injection by enabling easier and more accurate dose recording, dose calculations, and sharing of diabetes management data with clinicians. This article also discusses new roles for diabetes care and education specialists in diabetes data-driven care and practice and addresses how smart insulin pens represent one of many newer digital diabetes management tools that can assist people with diabetes and their clinicians to optimally achieve and deliver quality, data-driven diabetes care.

Conclusions

Newer and simplified insulin delivery devices with their integrated management systems, such as smart insulin pens, have the potential to minimize the challenges and complexities associated with insulin injection therapy while also providing people with diabetes and their clinicians more complete and integrated data in easily transmitted reports that support more efficient data analysis.

Get full access to this article

View all access options for this article.

References

ADA. This history of a wonderful thing we call insulin. Accessed March 10, 2020. https://www.diabetes.org/blog/history-wonderful-thing-we-call-insulin

Selam

JL.

Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4(3):505-513.

Calibra Finesse to CeQur bolus patch. Med Device Online. Calibra gains FDA clearance to market Finesse^TM insulin patch-pen for three-day use with Novolog®. Accessed March 11, 2020. https://www.meddeviceonline.com/doc/calibra-gains-fda-clearance-to-market-finesse-0001

MannKind Corporation. MannKind corporation announces FDA approval of AFREZZA(R); A novel, rapid-acting inhaled insulin for the treatment of diabetes. Accessed March 10, 2020. http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-announces-fda-approval-afrezzar-novel-rapid

PR Newswire. Valeritas receives FDA 510(k) clearance for the V-Go disposable insulin delivery device for use with NovoLog. https://www.prnewswire.com/news-releases/valeritas-receives-fda-510k-clearance-for-the-v-go-disposable-insulin-delivery-device-for-use-with-novolog-117142478.html. Accessed May 26, 2020.

Companion Medical. FDA clearance of InPen. Accessed March 11, 2020. https://www.accessdata.fda.gov/cdrh_docs/pdf16/K160629.pdf.

Association of Diabetes Care & Education Specialists. A vision for the future. Accessed March 11, 2020. https://www.diabeteseducator.org/about-adces/For-Diabetes-Care-and-Education-Specialists

Association of Diabetes Care & Education Specialists. AADE rebrands as Association of Diabetes Care & Education Specialists. Accessed February 24, 2020. https://www.diabeteseducator.org/news-and-publications/press-releases/press-releases/2020/01/22/aade-rebrands-as-association-of-diabetes-care-education-specialists

Association of Diabetes Care & Education Specialists. A statement from AADE – a new title for the specialty. Accessed February 24, 2020. https://www.diabeteseducator.org/news-and-publications/press-releases/press-releases/2019/08/20/a-statement-from-the-american-association-of-diabetes-educators—a-new-title-for-the-specialty

10.

Ryan

Burke

Litchman

, et al. Competencies for Diabetes Care and Education Specialists. Diabetes Educ. 2020;46(4):384-397.

11.

Greenwood

Howell

Scher

, et al. A framework for optimizing technology-enabled diabetes and cardiometabolic care and education: the role of the diabetes care and education specialist. Diabetes Educ. 2020;46(4):315-322.

12.

Isaacs

Cox

Schwab

, et al. Technology integration: The role of the diabetes care and education specialist in practice. Diabetes Educ. 2020;46(4):323-334.

13.

Kaufman

Mel

Using digital health technology to prevent and treat diabetes. Diabetes Technol Ther. 2020;22(suppl 1):S63-S78.

14.

Levine

Gabbay

RA.

Reviewing

U.S.

connected diabetes care: the newest member of the team. Diabetes Technol Ther. 2020;22(1):1-9.

15.

Saydah

SH.

Medication use and self-care practices in persons with diabetes. In: Cowie

Casagrande

Menke

, et al., eds. Diabetes in America. 3rd ed. National Institutes of Health; 2017 (NIH publ. no. 17-1468).

16.

American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(suppl 1):S14-S31.

17.

JDRF Statistics. Type 1 diabetes facts. Accessed February 21, 2020. https://www.jdrf.org/t1d-resources/about/facts/

18.

Bailey

Stone

JY.

A novel pen-based Bluetooth-enabled insulin delivery system with insulin dose tracking and advice. Expert Opin Drug Deliv. 2017;14(5):697-703.

19.

Kerr

Warshaw

Choi

NY.

Smart insulin pens will address critical unmet needs for people with diabetes using insulin. Endocrine Today. 2019;(May):20-21.

20.

American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes - 2020. Diabetes Care. 2020;43(suppl 1):S77-S88.

21.

Sikes

Weyman

. Diabetes and the use of insulin pumps. Endocrinology Advisor. Accessed March 11, 2020. https://www.endocrinologyadvisor.com/home/decision-support-in-medicine/endocrinology-metabolism/diabetes-and-the-use-of-insulin-pumps/

22.

Foster

Beck

Miller

, et al. State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.

23.

Grip

Svensson

Miftaraj

, et al. Real-world costs of continuous insulin pump therapy and multiple daily injections for type 1 diabetes: a population-based and propensity-matched cohort from the Swedish National Diabetes Register. Diabetes Care. 2019;42(4):545-552.

24.

MacLeod

Enterprising diabetes educators embrace digital health. Practical Diabetology. 2019;38(1):15-17.

25.

Yeh

H-C

Brown

Maruthur

, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336-347.

26.

Soupal

Petruzelkova

Grunberger

, et al. Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the COMISAIR Study. Diabetes Care. 2020;43(1):37-43.

27.

Kerr

Klonoff

DC.

Digital diabetes data and artificial intelligence: a time for humility and not hubris. J Diabetes Sci Technol. 2019;13:123-127.

28.

Norlander

Anderson

Levy

, et al. Late and missed meal boluses with multiple daily insulin injections. Diabetes. 2018;67(suppl 1).

29.

Munshi

Slyne

Greenberg

, et al. Nonadherence to insulin therapy detected by Bluetooth-enabled pen cap is associated with poor glycemic control. Diabetes Care. 2019;42(6):1129-1131.

30.

Randlov

Poulsen

JU.

How much do forgotten insulin injections matter to hemoglobin A1C in people with diabetes? A simulation study. J Diabetes Sci Technol. 2008;2(2):229-235.

31.

Marden

Thomas

Sheppard

, et al. Poor numeracy skills are associated with glycaemic control in type 1 diabetes. Diabetes Med. 2011:29:662-669.

32.

Zaugg

Dogbey

Collins

, et al. Diabetes numeracy and blood glucose control. Association with type of diabetes and source of care. Clin Diabetes. 2014;32(4):152-157.

33.

Cavanaugh

Huizinga

Wallston

, et al. Association of numeracy and diabetes control. Ann Intern Med. 2008;148(10):737-746.

34.

Garg

Bookout

McFann

, et al. Improved glycemic control in intensively treated adult subjects with type 1 diabetes using insulin guidance software. Diabetes Technol Ther. 2008;10(5):369-375.

35.

Barnard

Parkin

Young

, et al. Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. J Diabetes Sci Technol. 2012;6:144-149.

36.

Schmidt

Meldgaard

Serifovski

, et al. Use of an automated bolus calculator in MDI-treated type 1 diabetes: the boluscal study, a randomized controlled pilot study. Diabetes Care. 2012;35(5):984-990.

37.

Ziegler

Cavan

Cranston

, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013;36(11):3613-3619.

38.

Toschi

Slyne

Greenberg

, et al. Examining the relationship between pre- and postprandial glucose levels and insulin bolus timing using Bluetooth-enabled insulin pen cap technology and continuous glucose monitoring. Diabetes Technol Ther. 2020;22(1):19-24.

39.

FDA. Consumers (medical devices). Accessed March 10, 2020. https://www.fda.gov/medical-devices/resources-you-medical-devices/consumers-medical-devices#How_are_Medical_Devices_Classified

40.

Sangave

Aungst

Patel

DK.

Smart connected insulin pens, caps and attachments: a review of the future of diabetes technology. Diabetes Spectr. 2019;32(4):378-384.

41.

Pennic

. Novo Nordisk integrates smart insulin pens with Medtronic continuous glucose monitoring (CGM) devices. Accessed March 11, 2020. https://hitconsultant.net/2019/09/16/novo-nordisk-integrates-smart-insulin-pens-with-medtronic-cgm-devices/#.XjNN0mhKiUk

42.

DIABNEXT CLIPSULIN. Accessed April 22, 2020. https://www.diabnext.com/clipsulin-c3/

43.

Common Sensing Gocap. Accessed April 22, 2020. https://gocap.me/

44.

FDA. Class I/II exemptions. Accessed April 20, 2020. https://www.fda.gov/medical-devices/classify-your-medical-device/class-i-ii-exemptions

45.

WCG FDA News. Companion Medical’s InPen system gains approval. Accessed March 11, 2020. https://www.fdanews.com/articles/187696-companion-medicals-inpen-system-gains-approval

46.

Companion Medical. Companion Medical’s InPen diabetes management system receives FDA clearance for use with Fiasp® insulin. Accessed March 11, 2020. https://www.prnewswire.com/news-releases/companion-medicals-inpen-diabetes-management-system-receives-fda-clearance-for-use-with-fiasp-insulin-301008297.html

47.

Aanstoot

Rodriquez

Weinzimer

Vint

Koeneman

Precision dosing of rapid-acting insulin matters. Diabetes Tech and Technol. 2020;22(5):1-6.

48.

Aleppo

Webb

Continuous glucose monitoring integration in clinical practice a stepped guide to data review and interpretation. J Diabetes Sci Technol. 2019;13(4):664-673.

49.

Polonsky

WH.

Psychosocial aspects of diabetes technology adult perspective. Endocrinol Metab Clin N Am. 2020;49:143-155.

50.

Battelino

Danna

Bergental

, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-1603.

51.

Reid

Gao

Gill

, et al. How much is too much? Outcomes in patients using high-dose insulin glargine. Int J Clin Pract. 2016;70(1):56-65.

52.

Walsh

Roberts

Pumping Insulin. 6th ed. Torrey Pines Press; 2017.

53.

Evert

Dennsion

Gardner

, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42(5):731-754.

54.

Stanford University. Diabetes Wise website. Accessed March 11, 2020. https://diabeteswise.org/.

55.

Greenwood

Gee

Fatkin

Peeples

A systematic review of reviews evaluating technology-enabled diabetes self-management education and support. J Diabetes Sci Technol. 2017;11(5):1015-1027.

56.

Centers for Medicare and Medicaid Services. MIPS improvement activities requirements. Accessed March 11, 2020. https://qpp.cms.gov/mips/improvement-activities

57.

Grunberger

Abelseth

Bailey

, et al. Consensus statement by AACE/ACE insulin pump management task force. Endocr Practice. 2014;20(5):463-489.

58.

Zinman

Morales

Stewart

, et al. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Res Care. 2017;8(4):739-752.

59.

Walsh

Roberts

Bailey

Guidelines for optimal bolus calculator settings in adults. J Diabetes Sci Technol. 2011;5(1):129-135.

60.

American Diabetes Association. 9. Pharmacological approaches to glycemic treatment: standards of medical care in diabetes – 2020. Diabetes Care. 2020;43(suppl 1):S98-S110.

61.

Centers for Medicare and Medicaid Services. Physician fee schedule CY 2020 final rule. Accessed March 11, 2020. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched